OCD1.F ChromaDex Corporation

Consumer Defensive Biotechnology Frankfurt Exchange
1.88 EUR
Close of Nov 13, 2026
1.62 6.05
Market cap
EUR 149M
P/E
18.8x
P/B
2.00x
ROE
9.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OCD1.F undervalued?

Graham number
Price1.88
Graham value1.45
Premium29.3%

OCD1.F trades 29.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ChromaDex Corporation fundamental analysis

No fundamental analysis for ChromaDex Corporation yet.

ChromaDex Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ChromaDex Corporation

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingred…

Full company profile